WST: CFO Robert McMahon granted 30,622 equity awards (08/11/2025)

Q: What equity awards did Robert W. McMahon receive according to the WST Form 4?

He received 15,838 restricted stock units (RSUs) and 14,784 stock options , for a total of 30,622 equity awards as reported.

Q: What are the terms of the stock options granted to the WST CFO?

The options have an exercise price of $240.33 , become exercisable beginning 08/11/2026 , and expire on 08/11/2035 .

Q: How do the RSU vesting schedules work for the reported grants?

One RSU award vests in three installments of 4,223; 6,335; and 2,112 shares over 6, 12 and 24 months; the other vests in four equal installments beginning 08/11/2026.

Q: Are the reported holdings direct or indirect for the WST reporting person?

The filing shows the holdings as Direct (D) beneficial ownership.

Q: Which issuer and ticker are associated with this Form 4?

The issuer is West Pharmaceutical Services, Inc. with ticker WST .

[Form 4] West Pharmaceutical Services, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Robert W. McMahon, SVP & Chief Financial Officer of West Pharmaceutical Services, Inc. (WST) received equity awards reported for transactions dated 08/11/2025. The awards include 15,838 restricted stock units (RSUs) granted at a $0 price and 14,784 stock options with a $240.33 exercise price. The options become exercisable beginning 08/11/2026 and expire 08/11/2035. The first RSU award vests in three installments (4,223; 6,335; 2,112), and the second vests in four equal annual installments beginning 08/11/2026. All reported holdings are shown as direct beneficial ownership.

Insights

TL;DR: Routine executive compensation: substantial equity granted to CFO, mixing RSUs and long-dated options with standard vesting.

The filing documents a typical compensation package for a senior executive comprising restricted stock units and stock options. The RSUs carry no purchase price and vest over one to two years depending on the award, supporting near- to medium-term retention. The options have a $240.33 exercise price, a one-year deferral to exercisability, and a nine-year remaining contractual life, consistent with multi-year incentive design. Reported ownership is direct, not indirect, indicating personal holdings by the reporting person.

TL;DR: Governance signals show alignment of CFO incentives with shareholders via equity grants, with clear vesting schedules.

The disclosure provides explicit vesting schedules for each award, which enhances transparency about when the CFO will realize economic interest. The combination of RSUs and options is a common mix to balance retention (RSUs) and performance/leverage (options). The report was filed by one reporting person and the transactions are recorded as direct beneficial ownership, meeting disclosure expectations under Section 16.

08/12/2025 - 07:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McMahon Robert W.

(Last)

(First)

(Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON

19341

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP & Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Rst. Stock Unit	$0	08/11/2025		A		12,670		⁽¹⁾	⁽¹⁾	Common Stock	12,670	$0	12,670	D
Rst. Stock Unit	$0	08/11/2025		A		3,168		⁽²⁾	⁽²⁾	Common Stock	3,168	$0	3,168	D
Stock Option (Right to Buy)	$240.33	08/11/2025		A		7,647		08/11/2026⁽²⁾	08/11/2035	Common Stock	7,647	$240.33	7,647	D
Stock Option (Right to Buy)	$240.33	08/11/2025		A		7,137		08/11/2026⁽²⁾	08/11/2035	Common Stock	7,137	$240.33	7,137	D

Explanation of Responses:

1. This award vests in three installments. 4,223 shares will vest six months from the grant date, 6,335 shares will vest 12 months from the grant date, and 2,112 shares will vest 24 months from the grant date.

2. This award vests in four equal installments beginning on August 11, 2026.

	/s/ Caitlin Hippeli, as an agent for Robert W. McMahon	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What equity awards did Robert W. McMahon receive according to the WST Form 4?

He received 15,838 restricted stock units (RSUs) and 14,784 stock options, for a total of 30,622 equity awards as reported.

What are the terms of the stock options granted to the WST CFO?

The options have an exercise price of $240.33, become exercisable beginning 08/11/2026, and expire on 08/11/2035.

How do the RSU vesting schedules work for the reported grants?

One RSU award vests in three installments of 4,223; 6,335; and 2,112 shares over 6, 12 and 24 months; the other vests in four equal installments beginning 08/11/2026.

Are the reported holdings direct or indirect for the WST reporting person?

The filing shows the holdings as Direct (D) beneficial ownership.

Which issuer and ticker are associated with this Form 4?

The issuer is West Pharmaceutical Services, Inc. with ticker WST.

AG真人官方

[Form 4] West Pharmaceutical Services, Inc. Insider Trading Activity

Insights

FAQ

What equity awards did Robert W. McMahon receive according to the WST Form 4?

What are the terms of the stock options granted to the WST CFO?

How do the RSU vesting schedules work for the reported grants?

Are the reported holdings direct or indirect for the WST reporting person?

Which issuer and ticker are associated with this Form 4?

NYSE:WST

WST Rankings

WST Latest News

WST Latest SEC Filings

WST Stock Data

AG真人官方

Trending News

[Form 4] West Pharmaceutical Services, Inc. Insider Trading Activity

Insights

Financial Analyst neutral

Corporate Governance Expert neutral

FAQ

What equity awards did Robert W. McMahon receive according to the WST Form 4?

What are the terms of the stock options granted to the WST CFO?

How do the RSU vesting schedules work for the reported grants?

Are the reported holdings direct or indirect for the WST reporting person?

Which issuer and ticker are associated with this Form 4?

NYSE:WST

WST Rankings

WST Latest News

WST Latest SEC Filings

WST Stock Data